SIGLEC5 antibody (C-Term)
Quick Overview for SIGLEC5 antibody (C-Term) (ABIN5534705)
Target
See all SIGLEC5 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 482-513, C-Term
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This SIGLEC5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 482-513 amino acids from the C-terminal region of human SIGLEC5.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- For WB starting dilution is: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.5 mg/mL
-
Buffer
- Supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- SIGLEC5 (Sialic Acid Binding Ig-Like Lectin 5 (SIGLEC5))
-
Alternative Name
- SIGLEC5
-
Background
- SIGLECs are members of the immunoglobulin superfamily that are expressed on the cell surface. Most SIGLECs have one or more cytoplasmic immune receptor tyrosine-based inhibitory motifs (ITIM). SIGLECs are typically expressed on cells of the innate immune system, with the exception of the B-cell expressed SIGLEC6. Sequence analysis predicted that the 697-amino acid SIGLEC10 protein contains a signal peptide, an N-terminal V-set Ig-like domain and four C2-set Ig-like domains, five potential N-linked glycosylation sites, a transmembrane region, and a 126-residue cytoplasmic tail with 3 putative ITIMs. Northern blot analysis detected a major 3.0-kb SIGLEC10 transcript, with highest levels in spleen, lymph node, blood leukocytes, and appendix. Little or no expression was observed in pancreas, thyroid, and testis. Flow cytometric analysis demonstrated eosinophil-specific expression of SIGLEC10, but at a lower level than that of SIGLEC8. Expression was also detected on monocytes and a CD16-positive/CD56-negative natural killer-like lymphocyte population. After sialidase treatment, which is necessary for unmasking the sialic acid-binding site on SIGLECs interacting with cell surface sialic acids, cells expressing SIGLEC10 bound to red blood cells. Immunoprecipitation analysis indicated expression of a 100- to 120-kD monomeric protein, higher than the predicted molecular mass, suggesting that SIGLEC10 is glycosylated.
-
Molecular Weight
- 61 kDa
-
Gene ID
- 8778
-
UniProt
- O15389
Target
-